Seer Inc Cl A (SEER) Stock Price, Quote & News

Company Profile

Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic in...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 453 0000

Website: seer.bio

Address:

3800 Bridge Parkway, Suite 102, Redwood City, United States

DonCorleone77 Jun. 1 at 8:44 PM

$SEER Seer announces the launch of a population-level study on biomakers Seer announced the launch of a population-level study aimed at identifying novel blood-based biomarkers that could lead to cancer diagnostics for young adults in their 20s and 30s. Relying on Seer's newly launched Proteograph ONE Assay and SP200 Automation Instrument along with the Thermo Scientific Orbitrap Astral mass spectrometer, this is the first large-scale plasma proteomics initiative of its kind to leverage mass spectrometry and AI-driven analytics to enhance early cancer detection and improve patient outcomes. Seer's latest platform advances will allow deep, unbiased proteomic analysis of 20,000 plasma samples in less time and cost than before.

0 · Reply

Armonica423 May. 10 at 11:58 PM

$SEER Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research

0 · Reply

GhostAlphaTrading Apr. 4 at 9:14 PM

$SEER 😎

0 · Reply

NVDAMillionaire Mar. 29 at 1:53 AM

$SEER Proteograph tech looks promising. Watching closely for more clinical validation and potential market expansion in 2025. Might nibble on small position. clear overview of current strategy: https://beyondspx.com/article/seer-inc-seer-a-pioneer-unlocking-the-secrets-of-the-proteome

0 · Reply

PenkeTrading Mar. 21 at 7:03 AM

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Seer Inc. Is that bullish or bearish? $SEER #RsiOversold #NASDAQ

0 · Reply

Shane_Drinion Feb. 18 at 6:29 PM

$SEER Feb 27 for 2024 financial results.

0 · Reply

OptionTrendz Feb. 5 at 5:24 PM

$SEER

0 · Reply

OptionTrendz Feb. 3 at 5:10 PM

$SEER bought 500 here

0 · Reply

Shane_Drinion Jan. 30 at 11:32 PM

$SEER A Thermo buyout seems inevitable.

0 · Reply

NVDAMillionaire Jan. 26 at 8:04 AM

$SEER Seer, Inc. (NASDAQ:SEER): Transforming Proteomics with Innovative Technology https://beyondspx.com/article/seer-inc-seer-transforming-the-proteomics-landscape-with-groundbreaking-technology

0 · Reply

Seer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults

May 29, 2025, 7:00 AM EDT - 5 weeks ago

Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency

May 13, 2025, 6:47 PM EDT - 7 weeks ago

Seer, Inc. (SEER) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 7 weeks ago

Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

Apr 24, 2025, 4:05 PM EDT - 2 months ago

Seer to Report First Quarter 2025 Financial Results on May 13, 2025

Feb 27, 2025, 10:09 PM EST - 4 months ago

Seer, Inc. (SEER) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 4 months ago

Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook

Feb 21, 2025, 7:00 AM EST - 4 months ago

Seer to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 7:00 AM EST - 4 months ago

Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025

Feb 13, 2025, 4:15 PM EST - 5 months ago

Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Jan 2, 2025, 4:05 PM EST - 6 months ago

Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference

Nov 21, 2024, 4:05 PM EST - 8 months ago

Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Nov 8, 2024, 7:00 AM EST - 8 months ago

Seer to Participate in Upcoming November Investor Conferences

Nov 6, 2024, 9:00 PM EST - 8 months ago

Seer, Inc. (SEER) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:03 PM EST - 8 months ago

Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific

Oct 31, 2024, 7:00 AM EDT - 8 months ago

Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer's, Lung Cancer, and More at ASHG 2024

Oct 21, 2024, 7:00 AM EDT - 9 months ago

Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer's, Population Health, and Xenotransplantation at HUPO 2024

Aug 22, 2024, 4:05 PM EDT - 11 months ago

Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 14, 2024, 4:05 PM EDT - 11 months ago

Seer Appoints Nicolas Roelofs to its Board of Directors

Aug 9, 2024, 7:00 AM EDT - 11 months ago

Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference

Jul 18, 2024, 4:03 PM EDT - 1 year ago

Seer to Report Second Quarter 2024 Financial Results on August 8, 2024

Jun 11, 2024, 11:11 AM EDT - 1 year ago

Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery

Jun 2, 2024, 10:55 AM EDT - 1 year ago

Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ's Early Cancer Detection Study

May 23, 2024, 9:17 AM EDT - 1 year ago

Lab Instrument Industry Update - New Commercial Entrants

AKYA BNGO CTKB DHR LAB MASS OMIC

May 8, 2024, 4:05 PM EDT - 1 year ago

Seer Reports First Quarter 2024 Financial Results

May 8, 2024, 4:03 PM EDT - 1 year ago

Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions

Apr 23, 2024, 4:05 PM EDT - 1 year ago

Seer to Report First Quarter 2024 Financial Results on May 8, 2024

Mar 1, 2024, 7:12 AM EST - 1 year ago

Seer, Inc. (SEER) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 4:05 PM EST - 1 year ago

Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook

Feb 21, 2024, 4:05 PM EST - 1 year ago

Seer to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 6, 2024, 8:00 AM EST - 1 year ago

Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery

Feb 1, 2024, 4:05 PM EST - 1 year ago

Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

Dec 21, 2023, 4:05 PM EST - 1 year ago

Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference

Nov 10, 2023, 9:00 AM EST - 1 year ago

Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum

Nov 8, 2023, 9:00 AM EST - 1 year ago

Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500

Nov 7, 2023, 10:31 PM EST - 1 year ago

Seer, Inc. (SEER) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:05 PM EST - 1 year ago

Seer Reports Third Quarter 2023 Financial Results

Nov 1, 2023, 9:00 AM EDT - 1 year ago

Seer Announces Addition of Panome Bio to Centers of Excellence (COE) Program

Oct 19, 2023, 4:05 PM EDT - 1 year ago

Seer to Report Third Quarter 2023 Financial Results on November 7, 2023

Sep 8, 2023, 4:05 PM EDT - 1 year ago

Seer to Participate in Upcoming September Investor Conferences

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Seer Reports Second Quarter 2023 Financial Results

Jul 27, 2023, 4:05 PM EDT - 2 years ago

Seer to Present at the Canaccord Genuity 43rd Annual Growth Conference

Jul 13, 2023, 4:05 PM EDT - 2 years ago

Seer to Report Second Quarter 2023 Financial Results on August 8, 2023

Jun 7, 2023, 9:00 AM EDT - 2 years ago

Seer Collaborates to Make Scalable, Unbiased Proteomics Accessible to More Researchers via new Seer Technology Access Center

Jun 1, 2023, 9:00 AM EDT - 2 years ago

Seer Launches the Proteograph XT Assay Kit: Allowing Labs to Easily Expand Their View of the Proteome and Scale Their Studies

May 13, 2023, 6:38 PM EDT - 2 years ago

Seer, Inc. (SEER) Q1 2023 Earnings Call Transcript

May 9, 2023, 4:05 PM EDT - 2 years ago

Seer Reports First Quarter 2023 Financial Results

Apr 20, 2023, 4:05 PM EDT - 2 years ago

Seer to Report First Quarter 2023 Financial Results on May 9, 2023

Mar 29, 2023, 2:00 PM EDT - 2 years ago

Seer's Proteograph™ Product Suite identifies undiscovered links between protein variants and lung cancer progression

Mar 2, 2023, 10:32 PM EST - 2 years ago

Seer, Inc. (SEER) Q4 2022 Earnings Call Transcript

DonCorleone77 Jun. 1 at 8:44 PM

0 · Reply

Armonica423 May. 10 at 11:58 PM

$SEER Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research

0 · Reply

GhostAlphaTrading Apr. 4 at 9:14 PM

$SEER 😎

0 · Reply

NVDAMillionaire Mar. 29 at 1:53 AM

0 · Reply

PenkeTrading Mar. 21 at 7:03 AM

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Seer Inc. Is that bullish or bearish? $SEER #RsiOversold #NASDAQ

0 · Reply

Shane_Drinion Feb. 18 at 6:29 PM

$SEER Feb 27 for 2024 financial results.

0 · Reply

OptionTrendz Feb. 5 at 5:24 PM

$SEER

0 · Reply

OptionTrendz Feb. 3 at 5:10 PM

$SEER bought 500 here

0 · Reply

Shane_Drinion Jan. 30 at 11:32 PM

$SEER A Thermo buyout seems inevitable.

0 · Reply

NVDAMillionaire Jan. 26 at 8:04 AM

$SEER Seer, Inc. (NASDAQ:SEER): Transforming Proteomics with Innovative Technology https://beyondspx.com/article/seer-inc-seer-transforming-the-proteomics-landscape-with-groundbreaking-technology

0 · Reply

Mrdsquared_ Jan. 6 at 10:31 PM

$SEER for me

0 · Reply

StockAutoPro Dec. 23 at 10:29 PM

$SEER: Seer Inc. innovates in proteomics. Buy at $2.25 targeting $5. Its unique technology for protein analysis offers untapped potential.

0 · Reply

StockAutoPro Dec. 21 at 10:27 PM

$SEER: Seer Inc. innovates in proteomics. Buy at $2.31 targeting $5. Its unique technology for protein analysis offers untapped potential.

0 · Reply

NVDAMillionaire Dec. 11 at 5:34 PM

$SEER Seer Inc (SEER): Transforming the Proteomics Landscape with Groundbreaking Technology https://beyondspx.com/article/seer-inc-seer-transforming-the-proteomics-landscape-with-groundbreaking-technology

0 · Reply

Doozio Dec. 11 at 2:07 AM

$SEER INTA 🧠⏰♾️

1 · Reply

PenkeTrading Nov. 15 at 8:31 AM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Seer Inc. Is that bullish or bearish? $SEER #RsiOverbought #NASDAQ

0 · Reply

DavyDaveCharts Nov. 11 at 6:40 PM

$SEER Swing trade idea: entry 2.22, risk 1.99 (10%) and target 3.07 (39.45% Profit). Weekly chart shows a breakout above the anchored VWAP resistance. I'd wait until we can confirm that this pull back is a new test of resistance flipped to support.

0 · Reply

keepbuying Nov. 7 at 2:21 PM

$SEER nice deal w thermo Fischer’s!! And trading way below cash! $TSBX https://finance.yahoo.com/news/seer-enters-co-marketing-sales-210300133.html

1 · Reply

Scanners_Free Nov. 6 at 9:04 PM

$SEER NEWS OUT

0 · Reply

Doozio Oct. 13 at 11:54 PM

Da FUTUre of 🧠⏰ is NOW to $SEER da 🐑 during 🧠⏰♾️

0 · Reply

briefingcom Oct. 7 at 12:10 PM

Gapping down: $LASE -50.9% $SEER -2.4% $AMZN -1.5%

0 · Reply

Market Cap	130.10M
Revenue (ttm)	14.17M
Net Income (ttm)	-86.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-611.15%
Debt to Equity Ratio	0.00

Volume	56,200
Avg Vol	291,492
Day's Range	N/A - N/A
Shares Out	58.87M
Stochastic %K	98%
Beta	1.57
Analysts	Sell
Price Target	$3.00